Tharimmune Approved as Super Validator on Canton Network
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 29 2026
0mins
Source: NASDAQ.COM
- Super Validator Role: Tharimmune has been approved as a super validator on the Canton Network, processing over 700,000 daily transactions with a monthly volume of $9 trillion, thereby enhancing its competitive edge in the digital asset space.
- Successful Fundraising: The company completed a direct offering worth approximately $55 million on January 23, 2026, issuing 1.80 million shares of common stock, with proceeds aimed at expanding its Canton digital asset strategy and general corporate purposes.
- Clinical Candidate Progress: TH104, Tharimmune's lead clinical candidate, has completed its Phase 1 trial and is ready for Phase 2, targeting ultrapotent opioid exposure and chronic pruritus in primary biliary cholangitis patients.
- Positive FDA Feedback: TH104 received constructive guidance from the FDA, planning to integrate specific technical elements to optimize its prophylactic program against ultrapotent opioids, showcasing its potential for military and chemical incident responders.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
